Clinical trials: Empagliflozin
Acute Myocardial Infarction (AMI), Type 2 Diabetes Mellitus (T2DM)
SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study
This observational, retrospective cohort study aims to evaluate the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitor use after acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- SGLT2i-AMI (NCT07198191)
- Testing
- SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), DPP4 inhibitors
- Where
- South Korea
- Volunteers
- 200,000 people
- Sponsor
- Yonsei University
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.
- Trial name
- NCT01422876
- Testing
- high dose FDC, BI 10773 high dose
- Where
- 211 sites in United States, Argentina and 20 more
- Volunteers
- 1,405 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Cardiovascular Effects of Empagliflozine
It has been shown that in patients with type 2 diabetes (T2D) at high risk for cardiovascular disease (CVD) who received Empagliflozine as compared with placebo had a lower rate of death from cardiovascular causes, non-fatal MI…
- Trial name
- EMP (NCT02918591)
- Testing
- Empagliflozine
- Volunteers
- 10 people
- Sponsor
- Tel Aviv University
Patients With Advanced Cancer Receiving Specialized Palliative Care
Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial
The pathophysiological implications of various cancer diseases and anti-cancer therapies is the occurrence of a cardiac disease-like phenotype with cardiac dysfunction, cardiac wasting, and cardiac homeostasis changes (incl.
- Trial name
- EMPATICC (NCT05636774)
- Testing
- Heart failure medication
- Where
- Germany
- Volunteers
- 97 people
- Sponsor
- University Hospital, Essen
Type II Diabetes
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of Piemonte association in the treatment of type 2 diabetes mellitus
- Trial name
- PIEMONTE (NCT05028140)
- Testing
- PIEMONTE, EMPAGLIFLOZIN, PIOGLITAZONE
- Where
- Brazil
- Volunteers
- 480 people
- Sponsor
- EMS
Diabetes, Diabetes Mellitus, Type II
The EMPA-FIT Study
This multicenter, open-label, prospective study randomized 46 drug-naïve adults with T2D (HbA1c 6.5%-10.0%) to receive empagliflozin (10 mg/day) or metformin (1,000 mg/day) for 12 weeks.
- Trial name
- EMPA-FIT (NCT06846411)
- Testing
- Empagliflozin 10 mg, Metformin
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Seoul National University Bundang Hospital
Healthy
A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together
The main objective of this trial is to investigate the relative bioavailability of vicadrostat and empagliflozin when administered in combination or individually.
- Trial name
- NCT07035457
- Testing
- Vicadrostat, Jardiance®
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Ischemic Cardiomyopathy
RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy
To compare the effects of physiology- and imaging-guided PCI combined with optimal medical therapy (OMT) versus OMT alone on the recovery of left ventricular systolic function in patients with ischemic cardiomyopathy and…
- Trial name
- IMPROVE-ICMP (NCT06930092)
- Testing
- Physiology-and imaging-guided PCI, Optimal medical treatment
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease, Acute Kidney Injury
Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion.
- Conditions
- Coronary Artery Disease, Acute Kidney Injury, Contrast-Induced Acute Kidney Injury, Percutaneous Coronary Intervention
- Trial name
- FLORENCE (NCT07231939)
- Testing
- Flozin
- Where
- Poland
- Volunteers
- 4,000 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Diabetes Mellitus
New Triple Therapy in Newly Diagnosed Type 2 Diabetes
The goal of this clinical trial is to learn the efficany of combination therapy with semaglutide, empagliflozin and pioglitazone versus standard therapy in newly diagnosed type 2 diabetes. The main objectives to achieve are: 1.
- Trial name
- NCT06946628
- Testing
- Group A (triple combination therapy group), Group B (standard therapy group)
- Where
- China
- Volunteers
- 296 people
- Sponsor
- Sun Yat-sen University
type1diabetes
Empagliflozin in Adolescent Diabetes
Empagliflozin, an inhibitor of the sodium glucose co-transporter 2 (SGLT2), reduces post-prandial glucose levels in adults with both type 2 and type 1 diabetes and importantly reduces both cardiovascular and renal complications…
- Trial name
- NCT04917692
- Testing
- Empagliflozin
- Where
- United States
- Sponsor
- Ohio State University
Genetic Polymorphisms, Heart Failure
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown further reductions in heart failure hospitalization, cardiovascular events, and mortality, especially for heart failure patients.
- Trial name
- NCT06201000
- Testing
- SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- October 6 University
Heart Failure With Reduced Ejection Fraction
Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction
To assess the effect of Empagliflozin on cardiac biomarkers, cardiac function at rest and during stress, cardiac hemodynamics, renal function, metabolism, daily activity level and health-related quality of life in stable…
- Trial name
- Empire HF (NCT03198585)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Denmark
- Volunteers
- 190 people
- Sponsor
- Morten Schou
Healthy
Relative Bioavailability BI 10773 and Metformin in Healthy Male Volunteers
The objective was to investigate a possible drug-drug interaction between BI 10773 and metformin when co-administered as multiple oral doses.
- Trial name
- NCT02172248
- Testing
- BI 10773, Metformin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Endothelial Dysfunction, Diabetes Mellitus, Type 1
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
The aim of study is impact of additional treatment with new antidiabetic drugs (semaglutide or empagliflozine) compared to control group in T1DM patients - impact on endothelial function measured by FMD and FPF, arterial…
- Conditions
- Endothelial Dysfunction, Diabetes Mellitus, Type 1, Biomarkers, Endothelial Progenitor Cells
- Trial name
- ENDIS (NCT05857085)
- Testing
- Semaglutide Pen Injector [Ozempic], Empagliflozin 10 MG
- Where
- Slovenia
- Volunteers
- 90 people
- Sponsor
- General and Teaching Hospital Celje
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
This is a study in adults with chronic heart failure. People with chronic heart failure may need to be hospitalised for their condition. Some people with chronic heart failure may eventually die from their condition.
- Trial name
- NCT03057951
- Testing
- Empagliflozin
- Where
- 619 sites in United States, Argentina and 21 more
- Volunteers
- 5,988 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Cognitive Protective Effect of Newer Antidiabetic Drugs
The proposed study aims to: 1. Explore the cognitive protective effects of SGLT2 inhibitors and DPP-4 inhibitors in patients attending diabetic clinics in Alexandria 2.
- Trial name
- NCT05347459
- Testing
- Dapagliflozin, Empagliflozin, Canagliflozin
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Alexandria University
Non-Alcoholic Fatty Liver Disease
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Trial name
- SHIELD (NCT06355310)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Justin Ryder
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects
Study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of single rising oral doses of BI 10773 to healthy male subjects.
- Trial name
- NCT02172170
- Testing
- BI 10773 single rising dose
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Heart Failure
Polypill Strategy for Heart Failure With Reduced Ejection Fraction
Heart failure with a reduced ejection fraction (HFrEF) represents a significant public health burden in the United States, with a growing prevalence particularly among African Americans and Hispanic Americans and individuals of…
- Trial name
- POLY-HF (NCT04633005)
- Testing
- Polypill, Control Rx
- Where
- United States
- Volunteers
- 212 people
- Sponsor
- University of Texas Southwestern Medical Center